Insider Selling: Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Sells 69,219 Shares of Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) Director Ankit Mahadevia sold 69,219 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total value of $53,990.82. Following the completion of the sale, the director now owns 689,866 shares in the company, valued at approximately $538,095.48. This represents a 9.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Spero Therapeutics Stock Up 16.4 %

NASDAQ SPRO traded up $0.12 during trading on Wednesday, hitting $0.88. The stock had a trading volume of 1,489,743 shares, compared to its average volume of 292,584. The company has a market capitalization of $47.81 million, a PE ratio of 12.53 and a beta of 0.61. Spero Therapeutics, Inc. has a twelve month low of $0.74 and a twelve month high of $1.89. The firm has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.19.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on SPRO shares. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a research report on Thursday, January 30th. Evercore ISI cut Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a report on Friday, December 20th. TD Cowen reiterated a “hold” rating on shares of Spero Therapeutics in a report on Monday, November 18th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.